(RTTNews) - Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company, on Monday announced the activation of multiple clinical sites in Poland for its Phase III clinical trial, FLAMINGO-01, which is evaluating its immunotherapy GLSI-100 to prevent breast cancer recurrences.
The trial focuses on HER2-positive breast cancer patients who have completed both neoadjuvant and adjuvant trastuzumab-based treatments.
The new Polish sites, led by Dr. Piotr Wysocki, one of Poland's leading breast cancer researchers, have been approved by Polish authorities.
These sites include prestigious institutions such as Jagiellonian University Hospital in Krakow and Samodzielny Publiczny Zaklad Opieki Zdrowotnej in Opole, with the first patient treated in late 2024.
Greenwich LifeSciences is expanding its trial globally, aiming for up to 150 sites across the U.S. and Europe.
The company's shares have seen a boost following the announcement, reflecting growing optimism for the trial's progress.
As of the latest financial report, Greenwich LifeSciences remains well-funded, with sufficient capital to support operations through at least the next two years.
This progress in the FLAMINGO-01 trial marks an important step forward in the company's efforts to provide innovative treatments for breast cancer patients and prevent recurrences.
GLSI is currently trading at $14.25 up by 8.89%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
